Table 3.
Differences between patients with a different left ventricular geometric pattern in the second examination. p Values of statistical significance (<0.05) and tendency (0.05–0.1) are shown
| NG2 | CR2 | CH2 | EH2 | p | |
|---|---|---|---|---|---|
| Number of patients (%) | 56 (65.1%) | 6 (7%) | 8 (9.3%) | 16 (18.6%) | |
| ∆ BMI (kg/m2) | 0.49 (−8.54–3.48) | 0.42 (−1.73–2.30) | 0.55 (−1.97–7.69) | 0.09 (−5.63–5.14) | ns |
| ∆ BMI-SDS | 0.11 (−5.26–1.23) | −0.16 (−0.52–0.72) | −0.16 (−0.92–2.61) | 0.13 (−1.76–1.60) | ns |
| ∆ WC (cm) | 0.25 (−23.5–8.5) | −0.75 (−7–3.5) | −1.5 (−4.5–18.5) | −2.5 (−17–4) | NG2 vs EH2 0.02 |
| ∆ WC-SDS | −0.13 (−4.04–0.99) | −0.29 (−1.45–0.03) | −0.39 (−0.98–1.97) | −0.45 (−2.22–0.50) | NG2 vs EH20.05 |
| ∆ WHR | 0 (−0.01–0.09) | −0.02 (−0.09–0.01) | −0.01 (−0.09–0.09) | −0.02 (−0.18–0.04) | ns |
| ∆ WHtR | 0 (−0.14–0.05) | −0.01 (−0.09–0.02) | −0.01 (−0.06–0.09) | −0.03 (−0.10–0.01) | NG2 vs EH2 0.007 |
| ∆ SBP/24h (mmHg) | −5 (−33–20) | −3 (−18–12) | −2 (−13–7) | −1 (−19–4) | ns |
| ∆ SBPI/24h | −0.05 (−0.29–0.27) | −0.03 (−0.14–0.09) | −0.02 (−0.16–0) | −0.04 (−1.01–0.01) | ns |
| ∆ DBP/24h (mmHg) | −2 (−30–19) | 1(−13–4) | 5 (−15–23) | −2 (−13–4) | CH2 vs NG2, EH2 < 0.05, CH2 vs CR2 0.10 |
| ∆ DBPI/24h | −0.03 (−1.04–0.25) | 0.01 (−0.16–0.05) | 0.06 (−0.20–0.30) | −0.03 (−0.77–0.13) | CH2 vs NG2, EH2 < 0.05, CH2 vs CR2 0.15 |
| ∆ TG/HDL | −0.11 (−5.77–2.63) | −0.04 (−1.59–0.85) | 0.94 (−0.77–4.41) | −0.12 (−2.45–1.50) | CH2 vs NG2, EH2 < 0.05 |
| ∆ HOMA-IR | −0.10 (−3.71–8.14) | −0.70 (−2.23–0.69) | 1.34 (−0.66–4.05) | 0.01 (−1.47–0.59) | CH2 vs CR2 < 0.05, CH2 vs NG2 0.1 |
| ∆ uric acid (mg/dl) | −0.1 (−2.7–0.8) | 0.2 (−0.5–1.6) | 0.1 (−0.2–2) | −0.7 (−2.4–2.7) | EH2 vs. CH2, CR2 < 0.05, EH2 vs NG2 0.05, |
| ∆ADMA | −0.06 (−0.58–0.53) | −0.11 (−0.33–0.07) | 0.33 (0.08–0.91) | −0.14 (−0.91–0.30) | CH2 vs NG2, CR2 < 0.05, CH2 vs EH2 0.08 |
NG2, normal geometry after 12 months of antihypertensive treatment; CR2, concentric remodeling after 12 months of antihypertensive treatment; CH2, concentric hypertrophy after 12 months of antihypertensive treatment; EH2, eccentric hypertrophy after 12 months of antihypertensive treatment; BMI, body mass index; WC, waist circumference; WHR, waist to hip ratio; WHtR, waist to high ratio; SBP/24h, mean systolic blood pressure in 24-h ambulatory blood pressure monitoring; SBPI/24h, index of mean systolic blood pressure in 24-h ambulatory blood pressure monitoring; DBP/24h, mean diastolic systolic blood pressure in 24-h ambulatory blood pressure monitoring; DBPI/24h, index of mean diastolic systolic blood pressure in 24-h ambulatory blood pressure monitoring; TG/HDL, triglycerides to high-density lipoprotein cholesterol ratio; HOMA-IR, homeostasis model assessment for insulin resistance; ADMA, serum asymmetric dimethyloarginine; SDS, standard deviation score